The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Highlights from ASCO GI 2021
Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, evaluates important trial updates presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including findings from the FIGHT study (NCT03694522), a Phase II trial of bemarituzumab, an FGFR2b targeting antibody in combination with modified FOLFOX6 (mFOLFOX6) in the first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Secondly, Dr Ahmed highlights the findings of a longitudinal study evaluating the prognostic value of circulating tumor DNA in patients with colorectal cancer. Dr Ahmed finishes by updating us on the results of the Alliance A021501 study (NCT02839343) in patients with pancreatic adenocarcinoma which investigated the use of preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
